Further processing options
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
Saved in:
Journal Title: | Cancer Research |
---|---|
Authors and Corporations: | , , , , , , , , , , , , , |
In: | Cancer Research, 64, 2004, 18, p. 6616-6625 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Association for Cancer Research (AACR)
|
Subjects: |